{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T10:06:16Z","timestamp":1780308376925,"version":"3.54.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijgc.2026.104676","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T23:56:19Z","timestamp":1775260579000},"page":"104676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Contemporary risk assessment and risk-reducing strategies for tubo-ovarian cancer in women with BRCA pathogenic variants"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9395-0627","authenticated-orcid":false,"given":"David","family":"Viveros-Carre\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4367-836X","authenticated-orcid":false,"given":"Isabel","family":"Beshar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Agust\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2507-5709","authenticated-orcid":false,"given":"Ananya","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4240-2227","authenticated-orcid":false,"given":"Nathalia","family":"Mora-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7306-5081","authenticated-orcid":false,"given":"Maria D.","family":"Iniesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4456-3765","authenticated-orcid":false,"given":"Karla","family":"Barajas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0654-0863","authenticated-orcid":false,"given":"Alexander","family":"Melamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Alejandro","family":"Rauh-Hain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni Nitecki","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.ijgc.2026.104676_bib1","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.3390\/diagnostics13213331","article-title":"Current and emerging strategies for tubo-ovarian cancer diagnostics","volume":"13","author":"Brincat","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104676_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104676_bib3","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104676_bib4","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104676_bib5","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"10.1016\/j.ijgc.2026.104676_bib6","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening randomized controlled trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104676_bib7","first-page":"1","article-title":"Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial","volume":"29","author":"Menon","year":"2025","journal-title":"Health Technol Assess"},{"issue":"14","key":"10.1016\/j.ijgc.2026.104676_bib8","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-15-2750","article-title":"Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk - combined results from two screening trials","volume":"23","author":"Skates","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104676_bib9","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/sj.bjc.6603725","article-title":"No efficacy of annual gynaecological screening in BRCA1\/2 mutation carriers; an observational follow-up study","volume":"96","author":"Hermsen","year":"2007","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104676_bib10","first-page":"CD012464","article-title":"Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations","volume":"8","author":"Eleje","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104676_bib11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/AOG.0b013e3182783c2f","article-title":"Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers","volume":"121","author":"Kwon","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104676_bib12","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/1471-0528.18075","article-title":"Salpingectomy with delayed oophorectomy versus salpingo-oophorectomy in BRCA1\/2 carriers: three-year outcomes of a prospective preference trial","volume":"132","author":"Van Bommel","year":"2025","journal-title":"BJOG"},{"key":"10.1016\/j.ijgc.2026.104676_bib14","article-title":"Guideline Committee. Ovarian cancer: identifying and managing familial and genetic risk-summary of new NICE guidance","volume":"385","author":"Slade","year":"2024","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104676_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","article-title":"Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline","volume":"34","author":"Sessa","year":"2023","journal-title":"Ann Oncol"},{"issue":"8033","key":"10.1016\/j.ijgc.2026.104676_bib17","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41586-024-07909-9","article-title":"Mechanism of BRCA1-BARD1 function in DNA end resection and DNA protection","volume":"634","author":"Ceppi","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104676_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2045-3701-3-11","article-title":"The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapy","volume":"3","author":"Zhang","year":"2013","journal-title":"Cell Biosci"},{"issue":"7763","key":"10.1016\/j.ijgc.2026.104676_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/d41586-019-02015-7","article-title":"New name for breast-cancer syndrome could help to save lives","volume":"571","author":"Pritchard","year":"2019","journal-title":"Nature"},{"issue":"7774","key":"10.1016\/j.ijgc.2026.104676_bib20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/d41586-019-02775-2","article-title":"Cancer: more genetic BRCA testing for men","volume":"573","author":"Marabelli","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ijgc.2026.104676_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.634217","article-title":"Germline structural variations in cancer predisposition genes","volume":"12","author":"P\u00f3cza","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.ijgc.2026.104676_bib22","unstructured":"Petrucelli N, Daly MB, Pal T. BRCA1\u2212 and BRCA2-associated hereditary breast and ovarian cancer. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. GeneReviews(\u00ae). University of Washington, Seattle. Accesed March 20, 2026. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1247\/"},{"key":"10.1016\/j.ijgc.2026.104676_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41525-018-0046-7","article-title":"Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices","volume":"3","author":"Toland","year":"2018","journal-title":"NPJ Genom Med"},{"issue":"13","key":"10.1016\/j.ijgc.2026.104676_bib24","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jama.2014.5985","article-title":"Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer","volume":"313","author":"Rebbeck","year":"2015","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104676_bib25","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jamaoncol.2025.3875","article-title":"Pathogenic variants, family history, and cumulative risk of breast cancer in US women","volume":"11","author":"O\u2019Brien","year":"2025","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104676_bib26","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/s41431-018-0111-9","article-title":"The association between cancer family history and ovarian cancer risk in BRCA1\/2 mutation carriers: can it be explained by the mutation position?","volume":"26","author":"Teixeira","year":"2018","journal-title":"Eur J Hum Genet"},{"issue":"24","key":"10.1016\/j.ijgc.2026.104676_bib27","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/jnci\/djq443","article-title":"Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations","volume":"102","author":"Metcalfe","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104676_bib28","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10549-009-0394-1","article-title":"Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers","volume":"119","author":"Milne","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104676_bib29","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ijc.29386","article-title":"Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers","volume":"137","author":"Kotsopoulos","year":"2015","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104676_bib30","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ygyno.2020.09.037","article-title":"Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation","volume":"159","author":"Kotsopoulos","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104676_bib31","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ejca.2010.04.018","article-title":"Oral contraceptive use and breast or ovarian cancer risk in BRCA1\/2 carriers: a meta-analysis","volume":"46","author":"Iodice","year":"2010","journal-title":"Eur J Cancer"},{"issue":"33","key":"10.1016\/j.ijgc.2026.104676_bib32","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2013.48.9021","article-title":"Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis","volume":"31","author":"Moorman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104676_bib33","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41436-018-0406-9","article-title":"BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors","volume":"21","author":"Lee","year":"2019","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104676_bib34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/1055-9965.EPI-20-1319","article-title":"CanRisk tool-A web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants","volume":"30","author":"Carver","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"13","key":"10.1016\/j.ijgc.2026.104676_bib35","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1200\/JCO.2016.69.9330","article-title":"Evidence of stage shift in women diagnosed with ovarian cancer during Phase II of the United Kingdom familial ovarian cancer screening study","volume":"35","author":"Rosenthal","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104676_bib36","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12943-022-01588-8","article-title":"Potential clinical utility of liquid biopsies in ovarian cancer","volume":"21","author":"Zhu","year":"2022","journal-title":"Mol Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104676_bib37","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s11864-024-01180-w","article-title":"Circulating tumor DNA (ctDNA) and its role in gynecologic malignancies","volume":"25","author":"Pomerantz","year":"2024","journal-title":"Curr Treat Options Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104676_bib38","doi-asserted-by":"crossref","first-page":"868","DOI":"10.5306\/wjco.v11.i11.868","article-title":"Liquid biopsy in ovarian cancer: catching the silent killer before it strikes","volume":"11","author":"Feeney","year":"2020","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104676_bib39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canlet.2019.10.014","article-title":"Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: ready for prime time?","volume":"468","author":"Asante","year":"2020","journal-title":"Cancer Lett"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104676_bib40","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1001\/jamaoncol.2023.6937","article-title":"Bilateral oophorectomy and all-cause mortality in women with BRCA1 and BRCA2 sequence variations","volume":"10","author":"Kotsopoulos","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijgc.2026.104676_bib41","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ygyno.2024.10.007","article-title":"What happens after menopause? (WHAM): a prospective controlled study of vasomotor symptoms and menopause-related quality of life 24 months after premenopausal risk-reducing salpingo-oophorectomy (RRSO)","volume":"191","author":"Hickey","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"28","key":"10.1016\/j.ijgc.2026.104676_bib42","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1200\/JCO.2005.02.626","article-title":"Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer","volume":"23","author":"Madalinska","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ijgc.2026.104676_bib43","doi-asserted-by":"crossref","DOI":"10.1111\/1471-0528.18304","article-title":"What happens after menopause (WHAM)? A progress report of a prospective controlled study of women after pre-menopausal risk-reducing bilateral salpingo-oophorectomy","author":"Price","year":"2025","journal-title":"BJOG"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104676_bib44","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s00198-025-07679-8","article-title":"Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on bone mineral density","volume":"36","author":"Beekman","year":"2025","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104676_bib45","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/path.1000","article-title":"Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer","volume":"195","author":"Piek","year":"2001","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104676_bib46","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/cam4.2725","article-title":"The fallopian tube as origin of ovarian cancer: change of diagnostic and preventive strategies","volume":"9","author":"Kyo","year":"2020","journal-title":"Cancer Med"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104676_bib47","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1097\/IGC.0b013e3182a80ac8","article-title":"Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC)","volume":"23","author":"Wethington","year":"2013","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104676_bib48","doi-asserted-by":"crossref","first-page":"dju410","DOI":"10.1093\/jnci\/dju410","article-title":"Ovarian cancer risk after salpingectomy: a nationwide population-based study","volume":"107","author":"Falconer","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijgc.2026.104676_bib49","series-title":"Clinical practice statement: salpingectomy for ovarian cancer prevention [Internet]","year":"2013"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104676_bib50","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1097\/AOG.0000000000003164","article-title":"774: opportunistic salpingectomy as a strategy for epithelial ovarian cancer prevention","volume":"133","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104676_bib51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41416-019-0446-1","article-title":"International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation","volume":"121","author":"Metcalfe","year":"2019","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104676_bib52","doi-asserted-by":"crossref","first-page":"508.e1","DOI":"10.1016\/j.ajog.2021.06.070","article-title":"Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations","volume":"225","author":"Smith","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ijgc.2026.104676_bib53","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ygyno.2023.04.006","article-title":"Patient perspectives on risk-reducing salpingectomy with delayed oophorectomy for ovarian cancer risk-reduction: a systematic review of the literature","volume":"173","author":"Perez","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104676_bib54","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/jamaoncol.2021.1590","article-title":"Association of salpingectomy with delayed oophorectomy versus salpingo-oophorectomy with quality of life in BRCA1\/2 pathogenic variant carriers: a nonrandomized controlled trial","volume":"7","author":"Steenbeek","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104676_bib55","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/ijgc-2020-001541","article-title":"Preventing Ovarian Cancer through early excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial","volume":"31","author":"Gaba","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2026.104676_bib56","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2019.04.055","article-title":"WISP: a prospective, multi-center trial of salpingectomy with delayed oophorectomy versus risk reducing salpingo-oophorectomy in women at increased risk for hereditary ovarian cancer","volume":"154","author":"Lu","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104676_bib57","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.ygyno.2024.07.043","article-title":"Sexual function and menopausal symptoms among patients at high risk of ovarian carcinoma undergoing interval salpingectomy or risk-reducing salpingo-oophorectomy in the prospective multicenter WISP trial","volume":"190","author":"Norquist","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104676_bib58","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations","volume":"2","author":"Shu","year":"2016","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104676_bib59","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2018.12.014","article-title":"Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits","volume":"153","author":"Gordhandas","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104676_bib60","first-page":"e16","article-title":"Risk-reducing salpingo-oophorectomy and the use of hormone replacement therapy below the age of natural menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66","volume":"129","author":"Manchanda","year":"2021","journal-title":"BJOG"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104676_bib61","doi-asserted-by":"crossref","first-page":"917","DOI":"10.6004\/jnccn.2015.0106","article-title":"Menopausal hormone therapy influence on breast cancer outcomes in the Women\u2019s Health Initiative","volume":"13","author":"Chlebowski","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104676_bib62","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/jso.26812","article-title":"Cancer risk-reducing surgery: Brazilian society of surgical oncology guideline part 1 (gynecology and breast)","volume":"126","author":"Carneiro","year":"2022","journal-title":"J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104676_bib63","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12282-023-01531-9","article-title":"The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2022 edition","volume":"31","author":"Kawai","year":"2024","journal-title":"Breast Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26002070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26002070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:33:05Z","timestamp":1780306385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26002070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1048891X26002070"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104676","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary risk assessment and risk-reducing strategies for tubo-ovarian cancer in women with BRCA pathogenic variants","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104676","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104676"}}